CSIMarket
 
Unicycive Therapeutics Inc   (UNCY)
Other Ticker:  
 
 
Price: $1.4300 $-0.03 -2.055%
Day's High: $1.51 Week Perf: 0.00
Day's Low: $ 1.42 30 Day Perf: 9.16 %
Volume (M): 202 52 Wk High: $ 2.49
Volume (M$): $ 289 52 Wk Avg: $1.11
Open: $1.47 52 Wk Low: $0.47



 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 33
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Unicycive Therapeutics Inc
Unicycive Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of various diseases. The company employs a unicyclic peptide platform technology, which allows for the design and development of novel peptide-based drugs.

Unicycive Therapeutics focuses on addressing unmet medical needs in areas such as cardiovascular diseases, oncology, and autoimmune disorders. Their research and development efforts are aimed at discovering and developing therapeutics that can effectively target specific disease mechanisms and provide improved treatment outcomes.

The company's unicyclic peptide platform technology enables the design of targeted therapies with enhanced stability, specificity, and efficacy. By combining the advantages of peptides' natural properties with the cyclic structure, Unicycive Therapeutics aims to develop drugs that can address complex biological targets.

Overall, Unicycive Therapeutics Inc is dedicated to advancing the field of therapeutics through innovative peptide-based drug development, with a focus on improving patient outcomes in a range of diseases.


   Company Address: 4300 El Camino Real Los Altos 94022 CA
   Company Phone Number: 351-4495   Stock Exchange / Ticker: NASDAQ UNCY
   UNCY is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Unicycive Announces $50 Million Private Placement: Expanding Investor Base and Progressing towards Key Milestones

Published Thu, Mar 14 2024 11:03 AM UTC


In an exciting move for Unicycive Therapeutics Inc, the company has recently announced a successful private placement that has secured $50 million in investment. This funding round was led by new investors Octagon Capital and Great Point Partners, LLC, with participation from other new and existing investors, including Logos Capital, Nantahala Capital, SilverArc Capital...

Stock Market Announcement

OLC Aims to Revolutionize the Multibillion-Dollar Hyperphosphatemia Market: Topline Data from Pivotal Trial Expected in Q2 2024

Published Tue, Jan 23 2024 12:03 PM UTC



In the world of biopharmaceuticals, research and development efforts are constantly underway to address pressing medical needs and advance patient care. One such endeavor is currently being pursued by OLC, a leading pharmaceutical company focused on tackling hyperphosphatemia. With fresh topline data from their pivotal trial anticipated in the second quarter of 202...

Product Service News

Breakthrough Hope: Unicycive Therapeutics' Pivotal Clinical Trial Aims to Revolutionize CKD on Dialysis Treatment

Published Mon, Dec 18 2023 12:03 PM UTC



Unicycive Therapeutics, a leading biopharmaceutical company, recently announced a significant step forward in the treatment of Chronic Kidney Disease (CKD) on dialysis. By enrolling the first patient in a pivotal clinical trial for Oxylanthanum Carbonate (OLC), Unicycive aims to potentially revolutionize the management of CKD, providing hope for millions of affecte...

Unicycive Therapeutics Inc

Enhanced Profitability Surges at UNCY during Third Quarter of 2023 Earnings Season



Unicycive Therapeutics Inc, a pharmaceutical company specializing in the development of innovative therapeutic solutions, recently announced its financial results for the third quarter of 2023. Despite challenging conditions in the market, the company managed to demonstrate substantial improvements in its earnings per share and overall financial performance. This article aims to outline the key facts and interpret these results to provide a comprehensive overview of Unicycive Therapeutics Inc's recent performance.
1. Earnings Per Share:
Unicycive Therapeutics Inc made significant progress in reducing its losses per share compared to the previous year. In Q3 2023, the company reported a loss per share of $-0.13, a notable improvement from the loss of $-0.37 per share in the same quarter the previous year. Additionally, the earnings per share increased by $0.04 compared to the preceding financial reporting period, where it stood at $-0.29 per share.

Unicycive Therapeutics Inc

Unicycive Therapeutics Inc witnesses soaring outlays, with financial performance under scrutiny as operating losses persist


As the reporting season for April to June 2023 resumes, a number of businesses, including several in the Major Pharmaceutical Preparations industry, have started revealing their financial numbers. Among them, UNCY, a pharmaceutical company, recently published an operating loss of $-4.322 million for the fiscal second quarter of 2023. This figure prompts us to analyze the recent direction of the company's financial performance.
Undeniably, the most direct measure of growth or decline is comparing the operating losses of consecutive quarters. In Q2 2022, UNCY's operating loss stood at $-3.636 million, which means that the company's financial position has weakened. While fluctuations and choppy periods are expected during the quest to develop a lucrative business strategy, UNCY's inability to significantly reduce its operating losses in this period is a concern.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com